Nexinhib20 (neutrophil exocytosis inhibitor 20) is a novel and potent protein-protein interaction inhibitor, inhibiting the interaction between the small GTPase Rab27a and its effector JFC1
(synaptotagmin-like protein1). Nexinhib20 inhibits exocytosis of
azurophilic granules in human neutrophils without affecting other
important innate immune responses including phagocytosis and neutrophil
extracellular trap production. Nexinhib20 prevents the expression of cytochrome b558 in the plasma membrane. It modulates vesicular trafficking and neutrophil activities. Nexinhib20 reduces the systemic inflammation, mediated by neutrophils.